Insomnia, Schizoaffective Disorder, Schizophrenia
Conditions
Brief summary
Sleep problems are pervasive in people with schizophrenia. In our study, our goal is to determine whether we can alleviate sleep symptoms and improve quality of life and well-being in patients with major psychiatric disorders through cognitive behavioral therapy (CBT) delivered via the internet or in groups. At the same time, the study provides information on factors that are commonly associated with sleep and well-being in patients. The intervention study is conducted as a Randomized Controlled Clinical Trial (RCT), in which subjects are randomized into three groups: 1) Treatment as usual (TAU), 2) TAU and Internet-based therapy for insomnia (ICBT-I), and 3) TAU and group therapy for insomnia (GCBT-I).
Detailed description
Sleep is important for well-being. Lack of sleep and poor quality of sleep (Insomnia) are risk factors for psychiatric and somatic diseases such as depression, cardiovascular disease, diabetes and memory disorders and increases the risk of cognitive errors and accidents. Psychiatric patients suffer from a wide variety of sleep disorders. Insomnia symptoms are known to increase the likelihood of later depression and even the use of disability pensions due to depression. Various sleep disorders are also common in patients with schizophrenia. Previous studies on schizophrenia have reported-, symptoms of insomnia, especially the problem of falling asleep and poor sleep quality, circadian rhythm disruption, hypersomnolence and nightmares among the patients. Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based treatment for insomnia. CBT-I can be implemented as an individual treatment, on a group basis or via the internet. There is evidence that CBT-I can also be used to treat a patient with a major psychiatric disorders, but randomized clinical trials (RCT) have rarely been published. Our research is based on the hypothesis that symptoms of insomnia in patients with schizophrenia can improved by CBT-I and, further, by improving patients' sleep quality their health and quality of life can also be improved. The present study is designed to investigate the effect of two different treatment programs as compared to treatment as usual (TAU). The purpose of this study is to determine whether CBT-I can help relieve sleep symptoms and improve quality of life and well-being in patients with schizophrenia. At the same time, the study provides information on factors that are commonly associated with sleep and well-being in patients with major psychiatric disorders. The intervention study is conducted as an RCT, in which subjects are randomized into three groups: 1) Treatment as usual (TAU), 2) TAU and Internet-based therapy for insomnia (ICBT-I), and 3) TAU and group therapy for insomnia (GCBT-I). The aim of this ongoing randomized controlled trial is to recruit 84 - 120 participants from Hospital District of Helsinki and Uusimaa (HUS) Psychiatry Outpatient Clinics for Psychosis, and they have previously participated in the nationwide SUPER Finland study (a study on genetic mechanisms of psychotic disorders and a part of the Stanley Global Neuropsychiatric Genomics Initiative). The study is performed on a cycle basis with a target of 12 to 24 patients per cycle, randomly assigned to three intervention groups.
Interventions
BEHAVIORALiCBT-I
Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
BEHAVIORALGCBT-I
Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
Sponsors
University of Helsinki
Finnish Institute for Health and Welfare
Finnish Institute of Occupational Health
Helsinki University Central Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To participate in the study, patients must meet the following criteria: 1. Have previously participated in the nationwide SUPER Finland study (www.superfinland.fi, a study on genetic mechanisms of psychotic disorders and a part of the Stanley Global Initiative) and have given permission for subsequent contact. 2. Be currently in psychiatric care at HUS 3. Be 18 years of age or older 4. Have a serious mental disorder (schizophrenia or schizoaffective disorder) 5. Have a stable medical condition 6. Have self-reported sleep problems: difficulty falling asleep, difficulty staying asleep, poor quality of sleep, or dissatisfaction with sleep 7. Have access to an electronic inquiry and treatment program and use of e-mail 8. Be able to participate in a sleep group if randomized.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Insomnia Severity Index score (ISI) (Morin 2011) | baseline, 12, 24 and 36 weeks from the baseline | A 7-item questionnaire used to assess insomnia severity with a score ranging between 0 to 28. Each questionnaire item addresses an aspect about sleep that is rated by the respondent on a 5-point scale (i.e., 0=no problem to 4=very severe problem). |
| Change in the health-related quality of life (HRQoL) instrument 15D score (Sintonen, 2001) | baseline, 12, 24 and 36 weeks from the baseline | The 15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL) that can be used both as a profile and single index score measure. The maximum score is 1 (no problems on any dimension) and the minimum score is 0 (being dead). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-reported subjective mood collected through a digital smartphone app (AIDO Healthcare) | baseline to week 36 | 1-2 times a week by emoji scale 1-5 |
| Self-reported variables for sleep quantity and quality (adapted from Partinen 1996) | baseline, 12, 24 and 36 weeks from the baseline | Questions about sleep quantity and quality |
| Self-reported variables for chronotype (Horne 1976) | baseline, 12, 24 and 36 weeks from the baseline | Questions about chronotype (morningness-eveningness-) |
| Self-reported variables for dreaming and nightmares (adapted from Sandman 2015) | baseline, 12, 24 and 36 weeks from the baseline | Questions about dreaming and nightmares |
| Self-reported variables for tiredness, fatigue, subjective memory, stress and recovery (Lundqvist 2016) | baseline, 12, 24 and 36 weeks from the baseline | Questions about tiredness, fatigue, subjective memory, stress and recovery. Scale 1(very good) to 5(very poor). |
| Self-reported variables for functional ability (adapted from Tuomi 1998). | baseline, 12, 24 and 36 weeks from the baseline | Questions about functional ability. Scale 0(very poor) to 10(very good). |
| Self-reported variables for symptoms of depression (Korenke 2001) | baseline, 12, 24 and 36 weeks from the baseline | Questions about symptoms of depression. Scale 0(not at all) to 3 (Almost Always) |
| Self-reported variables for symptoms of psychosis (adapted from Haddoc 1999), | baseline, 12, 24 and 36 weeks from the baseline | Questions about presence, severity, and characteristics of hallucinations, delusions, confused and disturbed thoughts and lack of insight and self-awareness. |
| Self-reported subjective sleep quality collected through a digital smartphone app (AIDO Healthcare) | baseline to week 36 | 1-2 times a week by emoji scale 1-5 |
| Subjective measures of Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) (Morin 2007) | baseline, 12, 24 and 36 weeks from the baseline | DBAS-16 is a 16-item self reported questionnaire to measure people's beliefs and attitudes about their personal sleep situations. Items are ranked from 0, strongly disagree, to 10, strongly agree. Total score is mean of all questions, with a higher score representing more dysfunctional beliefs and attitude about sleep. |
| Self-reported Feedback Questionnaire | 12 weeks | Participants experiences from the intervention including habits of practice of the new skills, experience of the effect of the intervention on sleep, mood and lifestyle, alliance with the therapist, the positive and negative effects of the treatment are questioned after the treatment period. |
| Objective information on sleep from Actigraphy (ACG) data | baseline (1 week) and week 12(1 week) | The dataset from ACG includes Total Sleep Time (TST), Wake After Sleep Onset (WASO) Bed time, Get up time, Time in bed, Sleep efficiency (SE), Sleep Onset Latency (SOL), One minute immobility and Fragmentation index |
| Objective information on circadian rhythms from Actigraphy (ACG) data | baseline (1 week) and week 12(1 week) | The dataset from ACG includes Cosine peak, Light/Dark ratio, Lowest 5 onset, Maximum 10 onset, RA, IV and IS |
| Subjective sleep diary tracking | baseline (1 week) and week 12(1 week) | Each morning after waking participants completed the Sleep Diary during the ACG -monitoring period to provide a daily record of self-reported bedtime, get-up time, sleep duration, and daytime naps. |
| Objective information on activity from EMFIT Sleep Tracker data (Emfit Ltd) | baseline to week 13 | EMFIT device measures heart rate, breathing rate, movement activity every 4 seconds, sleep staging every 30 seconds, and heart rate variability every 3 minutes. |
| Objective information on recovery of the autonomic nervous system from EMFIT Sleep Tracker data (Emfit Ltd) | baseline to week 13 | EMFIT device measures heart rate, breathing rate, movement activity every 4 seconds, sleep staging every 30 seconds, and heart rate variability every 3 minutes. |
| Cognitive performance is measure with the psychomotor vigilance test (PVT) (Basner 2011) via a web-based interface | baseline, 12, 24 and 36 weeks from the baseline | PVT is a sustained-attention, reaction-timed task that measures the speed with which subjects respond to a visual stimulus |
| Self-reported variables for lifestyle | baseline, 12, 24 and 36 weeks from the baseline | Questions about exercise, usage of caffeine, alcohol, nicotine. |
| Self-reported subjective fatigue collected through a digital smartphone app (AIDO Healthcare) | baseline to week 36 | 1-2 times a week by emoji scale 1-5 |
Countries
Finland
Contacts
Primary ContactTiina M. Paunio, M.D., Ph.D.
Backup ContactTuula E. Tanskanen, RN, MHC
Outcome results
None listed